Abstract:
The present disclosure relates to compounds useful for the detection or modulation of target nucleic acids containing trinucleotide repeats. The present disclosure further relates to methods for treatment of trinucleotide repeat disorders such as polyglutamine diseases, which can include administration of oligonucleotide analogues that can bind pathogenic nucleotide repeats in DNA or RNA.
Abstract:
The invention discloses a method for preparation of mononitrated aromatic compounds in a liquid-liquid biphasic solvent system with aqueous nitric acid as one phase and ionic liquids (ILs) as the second phase, wherein the nitric acid is continuously exchanged during the reaction, or the water, that is generated during the reaction, is removed by addition of NO2 and an oxidizing agent during the reaction.
Abstract:
This application describes a compound represented by Formula (I): (I) wherein: Y is a biologically active organic core group comprising one or more of an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group, to which Z is covalently bonded; n is 1, 2, 3, 4 or 5; m is 1 or 2; Z is O, NR, or N; X 1 is a covalent bond or -CH 2 CH 2 -, X 2 is O or NR; and R comprises H or a substituted or unsubstituted group selected from an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group. Methods of preparing the compounds, methods of using the compounds, and pharmaceutical compositions comprising the compounds are described as well.
Abstract:
The present invention relates to a new process for the preparation of NO-donating compounds using a sulfonated intermediate. The invention relates to new intermediates prepared therein suitable for large scale manufacturing of NO-donating compounds. The invention further relates to the use of the new intermediates for the manufacturing of pharmaceutically active NO-donating compounds.The invention further relates to a substantially crystalline form of NO-donating NSAIDs, especially 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate, the preparation thereof and to pharmaceutical formulations containing said crystalline form and to the use of said crystalline form in the preparation of a medicament.
Abstract:
2,4-Dichloro-3-alkyl-6-nitrophenols which are useful as intermediate of cyan couplers in color photography are prepared by sulfonating 4-chloro-3-alkyl-phenols to obtain 5-chloro-4-alkylhydroxybenzenesulfonic acids, chlorinating the acids in an aqueous phase to obtain 3,5-dichloro-4-alkyl-2-hydroxybenzenesulfonic acids and nitrating the sulfonic acids.
Abstract:
Nouveaux dérivés de propargyloxybenzène Ils ont pour formule : avec X = H, Hal, CN, NO₂, NH₂ éventuellement alcoylé, alcoyle (C₁-C₁₂) alcoxy (C₁-C₁₂), alcoylthio (C₁-C₁₂) éventuellement halogéné, alkoxylé ou benzoxylé ; m = 0 à 5-n Y,Z = H, Hal n = 1,2 R₁ à R₄ = H₁, alcoyle inférieur
Abstract:
Process for the preparation of an aromatic hydrocarbon with a cyclobutene ring fused to the aromatic hydrocarbon which comprises, dissolving an ortho-alkyl halomethyl aromatic hydrocarbon in an inert solvent and pyrolyzing the solution of ortho-alkyl halomethyl aromatic hydrocarbon in the inert solvent under conditions such that the ortho-alkyl and the halomethyl substituents form a cyclobutene ring thereby forming an aromatic hydrocarbon having a fused cyclobutene ring. The ortho-alkyl group has the structural formula (R')2-CH-, wherein R' is separately in each occurance hydrogen or a C1-20 alkyl. The aromatic hydrocarbons with a cyclobutene ring fused to the aromatic hydrocarbon are useful in the preparation of monomers, which are then useful in the preparation of high performance polymers.
Abstract:
The present invention refers to a co-crystal of Ketoprofen Lysine named Form 1, a pharmaceutical composition comprising said co-crystal, a process for its production and to its use in the treatment of pain and inflammatory diseases.